Over 100 pharmaceutical listed companies competed to show their achievements of the third quarter in the end of October. Seen from comparison of absolute values of the corresponding period, performances of all pharmaceutical companies increased, but seen from the net profit growth, the whole industry declined. The major reason that slowed down the industrial growth speed was the slowing down of growth speed of medical insurance expenditure after medical insurance expense controlling. It was gratifying that the bio-pharmaceutical enterprises were “against the current”, which overall kept a relatively rapid growth speed. The innovative drug companies would have bright prospects in the future, especially the biological innovative drug companies, as predicted by an insider.
There were total 105 pharmaceutical listed companies in stock markets of Shanghai and Shenzhen having announced the third quarter report by October 31, the bad and good news being “20-80”. It is worth mentioning that Furui Medical Science, Xinbang Pharmaceutical and Kingdomway and other 11 companies realized double net profit. Following them, net profit growth of Jingxin Pharmaceutical, Jincheng Pharm, XPH and other 12 companies was 50%-100%.
The above achievements brought a bit of warmth to investors, however, the proportion of good forecast of pharmaceutical companies remained unchanged, but the internal growth speed slowed down by reference to financial data of previous years, and only bio-pharmaceutical enterprises outshone others.
